Patent intelligence · US
US 8076352
Administration of carboline derivatives useful in the treatment of cancer and other diseases
Administration of carboline derivatives useful in the treatment of cancer and other diseases
Patent details — US 8076352
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 13, 2011
- Expiration
- Dec 8, 2031
- Applicant
- PTC THERAPEUTICS, INC.
- Claims
- 18
- CPC classes
- A61K, A61K31/4353, A61K31/437, A61K31/444
Quick answer
US 8076352 (Administration of carboline derivatives useful in the treatment of cancer and other diseases) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Dec 13, 2011. Expires Dec 8, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PTC THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/4353, A61K31/437, A61K31/444, A61K31/5377, A61P
More from PTC THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12398140
Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
granted -
US 12384789
Compounds for treating Huntington's disease
granted -
US 12384797
Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
granted -
US 12281083
2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
granted -
US 12139499
Heteroaryl compounds for treating Huntington's disease
granted -
US 12103926
Compounds for treating huntington's disease
granted -
US 12023335
Method for treating pancreatic cancer
granted -
US 11938101
Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
granted
Frequently asked questions
What is US patent 8076352?
US 8076352 (Administration of carboline derivatives useful in the treatment of cancer and other diseases) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Dec 13, 2011. Expires Dec 8, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8076352?
PTC THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 149 pharmaceutical patents for this assignee.
When does US 8076352 expire?
Our index shows an expiration date of Dec 8, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.